JPRN-UMIN000045003招募中未知
Additional effect of luseogliflozin on semaglutide for non-alcoholic steatohepatitis patients with type 2 diabetes - Alight Study
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1. Patients who received SGLT2 inhibitors or GLP-1 receptor agonists within 3 months prior to the start of the drug administration study or after liver biopsy 2. Patients who used other SGLT2 inhibitors or GLP-1 receptor agonists during the study period 3. Patients with a history of serious adverse reactions to SGLT2 inhibitors or GLP-1 receptor agonists 4. Patients with uncompensated liver cirrhosis 5. Patients with serious renal disease 6. Patients with malignant tumor 7. Patients with a history of severe hypoglycemia 8. Patients with a history of ketoacidosis 9. Patients with a history of cerebral infarction with paralysis 10. Patients with urinary tract/genital infections or repeated urinary tract/genital infections 11. Patients with hepatitis due to other causes 12. Patients who were hospitalized for acute coronary syndrome, unstable angina, acute myocardial infarction, acute cerebral infarction, or transient ischemic attack within 3 months prior to obtaining consent 13. Pregnant or lactating women 14. Patients who had started or changed the dose of pioglitazone or vitamin E within 6 months prior to starting the study drug, or within 3 months prior to liver biopsy until starting the study drug 15. Patients who regularly use oral steroids or injectable steroids 16. Patients who are participating in other clinical studies using the study drug while participating in this study 17. If, in the opinion of the Principal Investigator, or others, participation in the research is not in the best interest of the research subject, or if it is judged to interfere with, limit, or confuse the specific evaluation of the clinical research protocol 18. A person under the direction of the Principal Investigator or the medical institution conducting the research, an employee of the Principal Investigator or of the medical institution directly involved in this or other clinical research, or family members of such employees or the Principal Investigator
研究者
相似试验
招募中
不适用
Additional effect of luseogliflozin on semaglutide for non-alcoholic steatohepatitis patients with type 2 diabetesonalcoholic steatohepatitisNonalcoholic steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD, NASHD065626JPRN-jRCTs061210009Hiasa Yoichi60
尚未招募
3 期
Impact of empagliflozin on nephrolithiasis among patients without diabetes compared to a placebo in reduction in the number and/or size of renal stonesephrolithiasisSLCTR/2023/012Professorial Medical Unit
招募中
2 期
Effect of SGLT2 Inhibition With Empagliflozin on Atrial Fibrillation Severity (SWEET-AF)Cardiovascular - Other cardiovascular diseasesAtrial FibrillationACTRN12621000208808The University of Adelaide300
进行中（未招募）
1 期
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH)on-alcoholic steatohepatitisMedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-004594-44-IEovo Nordisk A/S1,200
进行中（未招募）
1 期
Research study on whether semaglutide works in people with non-alcoholic steatohepatitis (NASH)on-alcoholic steatohepatitisMedDRA version: 24.1Level: PTClassification code 10053219Term: Non-alcoholic steatohepatitisSystem Organ Class: 10019805 - Hepatobiliary disordersEUCTR2019-004594-44-ROovo Nordisk A/S1,200